Vai al contenuto principale della pagina

Advance in the Treatment of Pediatric Leukemia



(Visualizza in formato marc)    (Visualizza in BIBFRAME)

Autore: Handgretinger Rupert Visualizza persona
Titolo: Advance in the Treatment of Pediatric Leukemia Visualizza cluster
Pubblicazione: Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022
Descrizione fisica: 1 electronic resource (300 p.)
Soggetto topico: Research & information: general
Chemistry
Soggetto non controllato: acute lymphoblastic leukemia
pediatric
advances
diagnosis
treatment
immunotherapy
bispecific T-cell engager (BiTE)
BCP-ALL
leukemia
TRAIL
antibody
Fc-engineering
xenograft
CD19
juvenile myelomonocytic leukemia
RAS signaling
hematopoietic stem cell transplantation
5-azacitidine
myelodysplastic/myeloproliferative disorders
targeted therapy
ADC
antibody-drug conjugate
pediatric leukemia
ALL
AML
allogeneic stem cell transplantation
acute myeloid leukemia
minimal residual disease
conditioning regimen
alternative donors
B-ALL
DUX4
IKZF1
PAX5
Ph-like
ZNF384
NUTM1
T-ALL
NOTCH1
BCL11B
transcriptome
genome
chronic myeloid leukemia
CML
tyrosine kinase inhibitor
immunizations
COVID-19
childhood acute lymphoblastic leukemia
low-risk ALL
risk-stratified treatment
treatment related toxicity
L-asparaginase
acute pancreatitis
polymorphism
SNV
ABCC4
CFTR
other extramedullary relapse
lymphoblastic leukemia
children
prognosis
evolution of CAR T cells
FDA-approved CAR products
TcR versus CAR
limitations and complications of CAR T cell therapy
future directions of CAR T cell therapy
Persona (resp. second.): HandgretingerRupert
Sommario/riassunto: The book gives an overview on the progress that has been made in the treatment of acute lymphoblastic leukemia (ALL), of acute and chronic myeloid leukemia (AML, CML) and of juvenile myelomonocytic leukemia (JMML). Leukemia is the most common malignant disease in children, and 80% of patients are diagnosed with ALL and 15–20% with AML, whereas CML and JMML are rather rare. Although ALL was considered an incurable disease until the early 1960s, with the availability of cytotoxic drugs and the start of clinical multicenter studies, ALL has become an almost curable disease with a survival rate exceeding 90 % in high-income countries. These impressive results have mainly been achieved by a deeper understanding of the genomic landscape of the disease and the introduction of risk stratifications based on genetic features and response to chemotherapy as determined by the presence or absence of minimal residual disease (MRD). Immunotherapies including bispecific T-cell Engagers (BiTEs), Chimeric Antigen Receptor (CAR) T cells, monoclonal antibodies and improvements in the outcome of allogeneic stem cell transplantation (HSCT) have shown impressive results in chemorefractory or relapsed patients, and it is anticipated that the cure rate can be further increased. For countries with less resources, therapies have to be adapted to increase survival as well. This book also updates on the progress made in the treatment of AML. As in ALL, risk classification based on genetic factors and response to chemotherapy is most important for therapy guidance. The book also provides updates and guidance for the treatment of CML and JMML.
Titolo autorizzato: Advance in the Treatment of Pediatric Leukemia  Visualizza cluster
Formato: Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione: Inglese
Record Nr.: 9910576878903321
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui